Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Now, Lilly has reinforced that finding with a strong of other measures, including that 32% of people taking Zepbound were able to lose a quarter of their body weight compared to 16% of the Wegovy ...

Group revenues came in at DKK 65.3 billion ($9.3 billion) – ahead of analyst expectations – with GLP-1 agonist Wegovy (semaglutide) contributing DKK 9.4 billion of the total.